|
Title
|
Published
|
Price
|
By
GBI Research
Report SummaryGBI Research’s report, Epigenetics Therapeutics to 2017 – High Market Potential for Epigenetics Drugs in Acute Myeloid Leukemia, Multiple Myeloma and Cutaneous T-Cell Lymphoma”, provid...
|
September 2010
|
$
3500
|
By
GBI Research
Report SummaryGBI Research's report, Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies”,...
|
September 2010
|
$
3500
|
By
Business Monitor International
BMI would describe South Korea as a transitional pharmaceutical market. Characteristic of an emerging market, combined sales of prescription drugs and over-the-counter (OTC) medicines are forecast to post high single-digit compound annual g...
|
August 2010
|
$
530
|
By
Business Monitor International
In our Q410 update, Taiwan has again retained sixth place – on a regional basis – in BMI’s Pharmaceuticals & Healthcare Business Environment Ratings, out of the 17 markets surveyed in Asia Pacific. Globally, Taiwan’s TWD123.4bn (US$3.81bn) ...
|
August 2010
|
$
530
|
By
Business Monitor International
In BMI’s Business Environment Ratings (BER) for Q410, Germany retained its position as the most attractive pharmaceutical market in Western Europe, out of the ten countries surveyed. The ratings criteria serve to reinforce our estimation of...
|
August 2010
|
$
530
|
By
Business Monitor International
In BMI's Q410 Pharmaceuticals & Healthcare Business Environment Ratings (BERs), the Western Europe region scored a total of 64.5 out of 100. The attractiveness of the region to pharmaceutical firms stems from the fact that its countries are...
|
August 2010
|
$
530
|
By
Business Monitor International
In BMI’s Business Environment Ratings (BERs) table for Q410, Slovenia is ranked ninth of the 20 markets assessed in CEE, up by one place in relation to the previous quarter. Overall, Slovenia’s attractiveness suffers from a small market siz...
|
August 2010
|
$
530
|
By
Business Monitor International
BMI’s outlook for pharmaceutical companies operating in the Emerging Europe region has improved further over the past quarter, as shown by our updated Pharmaceuticals and Healthcare Business Environment Ratings (BERs) matrix. However, while...
|
August 2010
|
$
530
|
By
Business Monitor International
BMI calculates Algerian pharmaceutical sales to have been DZD185.12bn (US$2.55bn) in 2009 and expects them to reach DZD208.56bn (US$2.84bn) in 2010. The market is characterised by a relatively low per-capita spend of US$73 (in 2009) and a l...
|
August 2010
|
$
530
|
By
Business Monitor International
While we continue to see Jordan as one of the moderately attractive markets in the Middle East and North Africa (MENA) region – with the country ranked 12th of the 19 regional markets by BMI’s Business Environment Ratings Table for Q410 – t...
|
August 2010
|
$
530
|
By
GlobalData
Report SummaryGlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – August 2010” report is an essential source of data and trend analysis on pa...
|
August 2010
|
$
1000
|
By
GBI Research
Report SummaryGBI Research’s Therapeutic Analysis report, Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinen...
|
August 2010
|
$
3500
|
By
GBI Research
Report SummaryGBI Research’s report, Women's Health Therapeutics Market to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in Menopause and Osteoporosis”, provides in-depth analysis of unm...
|
August 2010
|
$
3500
|
By
GBI Research
Report SummaryGBI Research has released its pharmaceutical industry research Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase T...
|
August 2010
|
$
3500
|
By
GBI Research
Report SummaryGBI Research's report, Pharmaceutical Contract Sales Organizations (CSO) - Emerging Markets to Drive Growth but Talent Acquisition in Specialty Secondary Care Remains a Challenge” provides key...
|
August 2010
|
$
3500
|
By
GlobalData
Report SummaryGlobalData’s pharmaceutical and healthcare report, Erectile Dysfunction - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analysis on the global E...
|
August 2010
|
$
2000
|
By
GlobalData
Report SummaryGlobalData, the industry analysis specialist, has released its new report, Type 2 Diabetes - Pipeline Assessemnt and Market Forecasts to 2017”. The report is an essential source of information and...
|
August 2010
|
$
2000
|
By
GlobalData
Report SummaryGlobalData, the industry analysis specialist, has released its new report, Endometriosis - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and a...
|
August 2010
|
$
2000
|
By
GlobalData
Report SummaryGlobalData, the industry analysis specialist, has released its new report, Urinary Incontinence - Pipeline Assessment and Market Forecasts to 2017” is an essential source of information and analys...
|
August 2010
|
$
2000
|
By
GlobalData
Report SummaryGlobalData, the industry analysis specialist, has released its new report, Women's Infertility - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of informa...
|
August 2010
|
$
2000
|
By
Business Monitor International
Report SummaryPharmaceutical firms have long regarded Nigeria with interest, chiefly because of its massive middleclass population and rising GDP, although we caution that much of that GDP depends on oil revenues. Cur...
|
August 2010
|
$
530
|
By
Business Monitor International
Report SummaryThe Philippines remains ranked 11th in our Asia Pacific Business Environment Ratings (BER) table for Q410. Globally, the country places 49th of the 83 markets now surveyed in our pharmaceutical universe,...
|
August 2010
|
$
530
|
By
Business Monitor International
Report SummaryBMI believes the recent unrest in Thailand will not have an immediate impact on pharmaceutical sales or the revenue earning opportunities of drugmakers because the demand for healthcare is relatively ind...
|
August 2010
|
$
530
|
By
Business Monitor International
Report SummaryPropped up by its large population, Poland has surfaced as one of the most important global emerging markets, with its value in 2009 calculated at PLN30.25bn (US$10.26bn) at retail prices. Over a five-ye...
|
August 2010
|
$
530
|
By
Business Monitor International
Report SummaryThe value of Argentina’s pharmaceutical market is calculated to have reached ARS12.64bn (US$3.37bn) in 2009. Through to 2014, we forecast a compound annual growth rate (CAGR) of 14.36% and 9.78% in...
|
August 2010
|
$
530
|
By
Business Monitor International
Report SummaryMeasured in local currency terms, Australia’s AUD10.07bn (US$7.74bn) pharmaceutical market is forecast to post a compound annual growth rate (CAGR) of 3.28% over the next 10 years (down from a rate...
|
August 2010
|
$
530
|
By
GlobalData
Report SummaryGlobalData, the industry analysis specialist’s new report, Chronic Kidney Disease - Pipeline Assessment and Market Forecasts to 2016” is an essential source of information and analysis on th...
|
July 2010
|
$
2000
|
By
Datamonitor
IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail distribution channels and 62 countries. This profile focuses on drug stores & health & bea...
|
July 2010
|
$
495
|
By
Datamonitor
IntroductionDatamonitor's retail databooks are based on key market value data for eight major product sectors, 16 core retail distribution channels and 62 countries. This profile focuses on drug stores and health and beauty ...
|
July 2010
|
$
495
|
By
Life Science Analytics
Report SummaryARCA biopharma, Inc.-Detailed Product Pipeline report contains detailed information on pipelines by phase and therapeutic indication as well as management information,deals and alliances and recent news ...
|
July 2010
|
$
750
|
By
Life Science Analytics
Report SummaryAccentia Biopharmaceuticals Inc-Detailed Product Pipeline Pipeline Report contains detailed information on pipelines by phase and therapeutic indication as well as management information,deals and allian...
|
July 2010
|
$
750
|
By
Life Science Analytics
Report SummaryACADIA Pharmaceuticals Inc-Detailed Product Pipeline Pipeline Report contains detailed information on pipelines by phase and therapeutic indication as well as management information,deals and alliances and rec...
|
July 2010
|
$
750
|
By
Life Science Analytics
Report SummaryAccess Pharmaceuticals Inc-Detailed Product Pipeline Pipeline Report contains detailed information on pipelines by phase and therapeutic indication as well as management information,deals and alliances and rec...
|
July 2010
|
$
750
|
By
Life Science Analytics
Report SummaryAchillion Pharmaceuticals Inc-Detailed Product Pipeline Pipeline Report contains detailed information on pipelines by phase and therapeutic indication as well as management information,deals and alliances and ...
|
July 2010
|
$
750
|
By
Life Science Analytics
Report SummaryAlcon Inc-Detailed Product Pipeline report contains detailed information on pipelines by phase and therapeutic indication as well as management information,deals and alliances and recent news on the company in...
|
July 2010
|
$
750
|
By
Datamonitor
IntroductionThis report covers key aspects of the traditional medicines market in four emerging / high growth economies: Brazil, Russia, India and China. Data is provided for market value by category, company and brand market sh...
|
July 2010
|
$
1995
|
By
Datamonitor
IntroductionThis report covers key aspects of the cough and cold preparations market in four emerging / high growth economies: Brazil, Russia, India and China. Data is provided for market value by category, company and brand mar...
|
July 2010
|
$
1995
|
By
Business Monitor International
Report SummaryBelarus came through the global economic crisis far more smoothly than neighbours such as Russia and Ukraine, a measure of the country’s disengagement from the broader European and global economies. In 2...
|
July 2010
|
$
530
|
By
Business Monitor International
Report SummaryIn BMI’s Business Environment Ratings for Emerging Europe in Q310, the Czech Republic retained its pole position, which it climbed to the previous quarter surpassing Greece. The country’s scores in...
|
July 2010
|
$
530
|
By
Business Monitor International
Report SummaryBMI’s Business Environment Ratings for the Middle East and Africa (MEA) pharmaceutical market underlines some of our key views for how the sector is performing in emerging markets. In particular we highl...
|
July 2010
|
$
530
|
By
Business Monitor International
Report SummaryIn BMI's Business Environment Ratings for Q310, the UK has maintained its fifth place out of the ten Western European markets surveyed. The ratings criteria serve to reinforce our estimation of the country...
|
July 2010
|
$
530
|
By
Business Monitor International
Report SummaryIn our updated Q310 Pharmaceutical Business Environment Ratings (BER) for the Americas, Venezuela remains third from the bottom, above Nicaragua and Honduras, with a pharmaceutical rating of 34.0. Globally, th...
|
July 2010
|
$
530
|
By
Business Monitor International
Report SummeryOur new Q310 Business Environment Ratings (BER) matrix for Emerging Europe places Lithuania in 15th position of the 20 markets surveyed. Lithuania’s pharmaceutical market score is the second-lowest in th...
|
July 2010
|
$
530
|
By
Business Monitor International
Report SummeryBMI’s Business Environment Ratings for the Middle East and Africa (MEA) pharmaceutical market underline some of our key views about how the sector is performing in emerging markets. In particular, we hig...
|
July 2010
|
$
530
|
By
Kalorama Information
What Will The Pharmaceutical Market Look Like in the Next Five Years?This research undertaking is the result of a detailed analysis of the late stage R&D pipeline of the 50 top companies in pharmaceuticals, the companies tha...
|
July 2010
|
$
4500
|
By
Business Monitor International
A population of just 738,000 limits the overall pharmaceutical market in Bahrain. In 2009 Bahrain’spharmaceutical market was worth just BHD43mn (US$112mn) but this is expected to reach BHD54mn(US$142mn) in 2014. However, BMI expec...
|
July 2010
|
$
530
|
By
Business Monitor International
Since the last quarter, we have revised our forecast slightly downward for Brazil as a result of concerns over thepersisting fiscal slippage and the increasing role of politics in the economy in the run-up to October’s elections.H...
|
July 2010
|
$
530
|
By
Business Monitor International
In BMI’s updated Americas Business Environment Ratings (BER) for Q310, Canada remains in secondplace in the expanded regional matrix, a position to which it rose in the previous quarter, having movedpast Puerto Rico. On a global s...
|
July 2010
|
$
530
|
By
Business Monitor International
In the Asia Pacific Pharmaceuticals & Healthcare BERs for Q310, China has maintained fourth positionof the 16 markets covered in Asia Pacific, with an above average pharmaceutical rating of 61.3. Chinascores highly for Pharmaceuti...
|
July 2010
|
$
530
|
By
Business Monitor International
France scores well in our Q310 Pharmaceuticals and Healthcare Business Environment Ratings – it isranked 10th globally (out of the 82 markets in BMI’s coverage universe) and fourth in our WesternEuropean matrix of nine countries. ...
|
July 2010
|
$
530
|